OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CXXI.CD55

C21 Investments Inc

Drug RetailersVerified

C21 Investments Inc has a current ratio of 0.51, indicating that its current assets are insufficient to cover its current liabilities, which suggests potential liquidity challenges. The company's debt-to-equity ratio is 0.04, reflecting a relatively low level of leverage compared to industry norms. However, the company's free cash flow is negative at -1.53 million USD, which may limit its ability to fund operations or invest in growth without external financing. The company's profitability is underperforming, with a return on equity of -6.58% and a return on assets of -3.74%, both significantly below the industry median. These metrics suggest that the company is not effectively utilizing its equity or assets to generate returns, which could be a concern for investors. C21 Investments Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to regional economic downturns or regulatory changes that could impact its primary market. The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year and no clear guidance for the next fiscal year. The negative operating income of -307,660 USD and net loss of -2.04 million USD indicate that the company is currently not generating sufficient revenue to cover its operating expenses. The company's risk profile includes medium liquidity risk due to its current ratio and negative free cash flow. While dilution risk is currently low, the negative net cash position after subtracting total debt suggests that the company may need to raise additional capital in the future, which could lead to share dilution. Recent filings and transcripts do not indicate any major strategic shifts or significant operational changes. The company's financial performance remains a key area of focus, with the need to improve profitability and manage liquidity effectively.

30-day price · CXXI.CD-0.06 (-15.0%)
Low$0.34High$0.54Close$0.34As of17 May, 00:00 UTC
Profile
CompanyC21 Investments Inc
TickerCXXI.CD
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryDrug Retailers
AI analysis

Business. C21 Investments Inc operates in the drug retailing industry, primarily generating revenue through the sale of pharmaceuticals and related health products.

Classification. C21 Investments Inc is classified under the Consumer Non-Cyclicals economic sector, Food & Drug Retailing business sector, and Drug Retailers industry with a confidence level of 0.92.

C21 Investments Inc has a current ratio of 0.51, indicating that its current assets are insufficient to cover its current liabilities, which suggests potential liquidity challenges. The company's debt-to-equity ratio is 0.04, reflecting a relatively low level of leverage compared to industry norms. However, the company's free cash flow is negative at -1.53 million USD, which may limit its ability to fund operations or invest in growth without external financing. The company's profitability is underperforming, with a return on equity of -6.58% and a return on assets of -3.74%, both significantly below the industry median. These metrics suggest that the company is not effectively utilizing its equity or assets to generate returns, which could be a concern for investors. C21 Investments Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to regional economic downturns or regulatory changes that could impact its primary market. The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year and no clear guidance for the next fiscal year. The negative operating income of -307,660 USD and net loss of -2.04 million USD indicate that the company is currently not generating sufficient revenue to cover its operating expenses. The company's risk profile includes medium liquidity risk due to its current ratio and negative free cash flow. While dilution risk is currently low, the negative net cash position after subtracting total debt suggests that the company may need to raise additional capital in the future, which could lead to share dilution. Recent filings and transcripts do not indicate any major strategic shifts or significant operational changes. The company's financial performance remains a key area of focus, with the need to improve profitability and manage liquidity effectively.
Key takeaways
  • C21 Investments Inc is experiencing negative returns on both equity and assets, indicating poor capital efficiency.
  • The company's liquidity position is weak, with a current ratio below 1 and negative free cash flow.
  • Revenue is not diversified across segments or geographies, increasing operational risk.
  • The company is not currently generating positive operating income and is reporting a net loss.
  • The risk of future capital raising and potential share dilution exists due to the company's negative net cash position.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$6.5M
Gross profit$2.8M
Operating income-$307.7k
Net income-$2.0M
R&D
SG&A
D&A
SBC
Operating cash flow$3.3M
CapEx-$521.6k
Free cash flow-$1.5M
Total assets$54.5M
Total liabilities$23.5M
Total equity$31.0M
Cash & equivalents
Long-term debt$1.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$33.5M$9.2M-$7.8M-$2.7M
FY-3$33.0M$9.8M$10.9M$12.4M
FY-2$28.9M$3.9M$293.2k$3.3M
FY-1$4.5M$289.9k-$74.4k
FY0$30.1M$1.3M-$4.0M-$4.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$66.8M$23.3M
FY-3$61.8M$33.7M
FY-2$58.3M$34.3M
FY-1$55.2M$31.0M
FY0$57.0M$28.7M
PeriodOCFCapExFCFSBC
FY-4$8.7M-$227.8k-$2.7M
FY-3$6.8M-$2.6M$12.4M
FY-2$5.9M-$442.3k$3.3M
FY-1$911.5k-$51.5k
FY0$1.2M-$3.8M-$4.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$6.5M-$307.7k-$2.0M-$1.5M
FQ-6$6.6M-$840.3k-$1.4M-$4.5M
FQ-5
FQ-4$7.9M$978.1k-$130.9k$484.1k
FQ-3$8.1M$837.2k-$1.6M-$846.1k
FQ-2$8.6M$207.4k-$758.8k-$57.7k
FQ-1$8.5M$785.8k-$486.7k$234.1k
FQ0$8.1M$354.2k-$610.7k$63.1k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$54.5M$31.0M
FQ-6$58.3M$31.0M
FQ-5
FQ-4$57.8M$30.4M
FQ-3$57.0M$28.7M
FQ-2$56.4M$27.9M
FQ-1$56.2M$27.3M
FQ0$54.9M$26.8M
PeriodOCFCapExFCFSBC
FQ-7$3.3M-$521.6k-$1.5M
FQ-6$561.0k-$3.6M-$4.5M
FQ-5
FQ-4$701.4k-$3.8M$484.1k
FQ-3$1.2M-$3.8M-$846.1k
FQ-2$490.5k-$37.3k-$57.7k
FQ-1$973.5k-$47.2k$234.1k
FQ0$951.6k-$102.4k$63.1k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$31.0M
Net cash-$1.2M
Current ratio0.5
Debt/Equity0.0
ROA-3.7%
ROE-6.6%
Cash conversion-1.6%
CapEx/Revenue-8.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
MetricCXXI.CDActivity
Op margin-4.7%3.1% medp25 1.2% · p75 6.8%bottom quartile
Net margin-31.2%2.0% medp25 0.7% · p75 4.1%bottom quartile
Gross margin43.5%26.1% medp25 17.2% · p75 32.0%top quartile
CapEx / revenue-8.0%-2.5% medp25 -4.6% · p75 -1.4%bottom quartile
Debt / equity4.0%56.0% medp25 16.8% · p75 121.1%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 06:54 UTC#d1ecb793
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 17:49 UTCJob: 49fbba8c